Jeffrey S Dover

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Placebo Controlled

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Conor J Gallagher, Ronald R Bowsher, Amanda Clancy, Jeffrey S Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 15 (1) (2023)
Conor J Gallagher, Ronald R Bowsher, Amanda Clancy, Jeffrey S Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 15 (1) (2023)
Conor J Gallagher, Ronald R Bowsher, Amanda Clancy, Jeffrey S Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 15 (1) (2023)
Conor J Gallagher, Ronald R Bowsher, Amanda Clancy, Jeffrey S Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 15 (1) (2023)
Conor J Gallagher, Ronald R Bowsher, Amanda Clancy, Jeffrey S Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials. Toxins 15 (1) (2023)